Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie - Update 2017∗: S3-Leitlinie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V., der Deutschen Gesellschaft für Infektiologie e.V., der Deutschen Gesellschaft für Hygiene und Mikrobiologie e.V., der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V., der Paul-Ehrlich Gesellschaft für Chemotherapie e.V, der Deutschen Röntgengesellschaft und der Gesellschaft für Virologie

Translated title of the contribution: Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017: S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology

K. Dalhoff*, M. Abele-Horn, S. Andreas, M. Deja, S. Ewig, P. Gastmeier, S. Gatermann, H. Gerlach, B. Grabein, C. P. Heuβel, G. Höffken, M. Kolditz, E. Kramme, H. Kühl, C. Lange, K. Mayer, I. Nachtigall, M. Panning, M. Pletz, P. M. RathG. Rohde, S. Rosseau, B. Schaaf, D. Schreiter, H. Schütte, H. Seifert, C. Spies, T. Welte

*Corresponding author for this work

Abstract

Nosocomial pneumonia (HAP) is a frequent complication of hospital care. Most data are available on ventilator-associated pneumonia. However, infections on general wards are increasing. A central issue are infections with multidrug resistant (MDR) pathogens which are difficult to treat in the empirical setting potentially leading to inappropriate use of antimicrobial therapy. This guideline update was compiled by an interdisciplinary group on the basis of a systematic literature review. Recommendations are made according to GRADE giving guidance for the diagnosis and treatment of HAP on the basis of quality of evidence and benefit/risk ratio. This guideline has two parts. First an update on epidemiology, spectrum of pathogens and antimicrobials is provided. In the second part recommendations for the management of diagnosis and treatment are given. New recommendations with respect to imaging, diagnosis of nosocomial viral pneumonia and prolonged infusion of antibacterial drugs have been added. The statements to risk factors for infections with MDR pathogens and recommendations for monotherapy vs combination therapy have been actualised. The importance of structured deescalation concepts and limitation of treatment duration is emphasized.

Translated title of the contributionEpidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017: S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology
Original languageGerman
JournalPneumologie
Volume72
Issue number1
Pages (from-to)15-63
Number of pages49
ISSN0934-8387
DOIs
Publication statusPublished - 01.01.2018

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017: S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology'. Together they form a unique fingerprint.

Cite this